CN106491596B - Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma - Google Patents
Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma Download PDFInfo
- Publication number
- CN106491596B CN106491596B CN201610819755.3A CN201610819755A CN106491596B CN 106491596 B CN106491596 B CN 106491596B CN 201610819755 A CN201610819755 A CN 201610819755A CN 106491596 B CN106491596 B CN 106491596B
- Authority
- CN
- China
- Prior art keywords
- trichoderma
- compound
- tangerine green
- lung cancer
- green trichoderma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The application that the invention discloses a kind of derived from the alkaloid compound of tangerine green trichoderma in terms of lung cancer.The structure feature of the compound is: the molecular skeleton containing five cyclic amides, connect a ten carbon saturated fat long-chains containing carbonyl, a methyl connected on N, there are two hydroxyl groups in molecule.It is verified by experiments, the alkaloid compound has preferable inhibitory activity to lung carcinoma cell, can be used for preparing proliferation of lung cancer cells and inhibits drug or anti-lung-cancer medicament, for antitumor research.
Description
Technical field
The application that the present invention relates to a kind of derived from the alkaloid compound mould enol E1 of tangerine green trichoderma in terms of lung cancer.
Background technique
Alkaloid is a kind of organic compounds containing nitrogen generated by biological cometabolism, the alkaloid type in nature compared with
It is more, greatly mostly from plant, therefore there is the title of vegetable soda again.Alkaloid has important physiological action to humans and animals, including flat
Antibechic, hypoglycemic, reducing blood lipid, antibacterial, antitumor, analgesia etc. are breathed heavily, wherein the most prominent with antibacterial, anti-tumor activity.Natural knot
Structure alkaloid is the important sources that lead compound is found in innovation drug research, has been applied to clinical alkaloidal drug at present
Through nearly hundred kinds.The study found that some marine fungis can generate structure novel, activity good biology during cometabolism
Alkali has good medicinal and industrialization prospect.
The present inventor studies and learns, tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4(is in 2013
On January 25, in is deposited in China typical culture collection center, and address: Wuhan Wuhan University, deposit number are: CCTCC NO:
M 2013055) the crude extract of tunning have good tumor cell proliferation inhibition activity, its active constituent is carried out then
Research.The study found that shown alkaloid compound has anti-tumor activity for lung cancer, and have not yet to see the compound
Chemical structure and its report for proliferation of lung cancer cells inhibitory activity, therefore in the market also there is not yet medicine related to this
Object.
Summary of the invention
The application that the purpose of the present invention is to provide a kind of derived from the alkaloid compound of tangerine green trichoderma in terms of lung cancer.
To achieve the above object, the present invention adopts the following technical scheme:
A kind of alkaloid compound derived from tangerine green trichoderma inhibits for proliferation of lung cancer cells the use in drug in preparation
On the way or the compound is preparing the purposes in anti-lung-cancer medicament；
The chemical structural formula of the compound are as follows:
；
Its structure feature is: the molecular skeleton containing five cyclic amides connects a ten carbon saturation containing a carbonyl
Connect that a methyl, there are two hydroxyl groups in molecule on fatty long-chain, N.
The compound be by tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4 progress fermented and cultured,
Then isolated from its mycelium and fermentation broth extract；The tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4 is deposited in China typical culture collection center on January 25th, 2013, address: Wuhan
Wuhan University, deposit number are: CCTCC NO:M 2013055.
Remarkable advantage of the invention is: present invention gained compound is the alkaloid of a structure novel, is had aobvious
The anti-lung cancer activity of work, and have not yet to see the chemical structure of the compound and its report for proliferation of lung cancer cells inhibitory activity
Road, therefore in the market also there is not yet drug related to this.
Detailed description of the invention
Fig. 1 is the present invention gained main COSY and HMBC signal of alkaloid compound.
Specific embodiment
The chemical structural formula of signified compound in the following example are as follows:
。
The fermenting and producing and separation and purification of 1 compound of embodiment
1. fermenting and producing
Produce bacterium fermented and cultured: by culture microorganism conventional method, take tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4(is deposited in China typical culture collection center on January 25th, 2013, address: Wuhan
Wuhan University, deposit number are: CCTCC NO:M 2013055) in right amount, it is inoculated into PDA solid slope culture medium, at 28 DEG C
It is cultivated 4 days in incubator.
Take inclined-plane culture 4 days tangerine green trichoderma (Trichoderma citrinoviride.) appropriate IBPT-4, it is inoculated into
Equipped with 400mL culture solution, [culture solution forms (grams per liter): mannitol 20.0, yeast extract 3.0, maltose 20.0, monosodium glutamate 10.0, Portugal
Grape sugar 10.0, KH2PO40.5, MgSO40.3, NaCl 6.0 constant volume] 1000mL conical flask in, 28 DEG C static gas wave refrigerator 30 days
Afterwards, mycelium and fermentation liquid are obtained.
2. the acquisition of medicinal extract
With gauze by mycelium and separation of fermentative broth.Fermentation liquid and ethyl acetate 1:2(v/v) are extracted twice, extract liquor
Vacuum distillation obtains the ethyl acetate extract of fermentation liquid to doing.Mycelium is then with the aqueous solution ultrasonication of the acetone containing 70%-80%
3 times, residue is removed, removal acetone is concentrated under reduced pressure after clear liquid is merged, 1:2 is added ethyl acetate and is extracted twice by volume, subtracts
Pressure is concentrated to dryness, and obtains mycelial ethyl acetate extract.It is mentioned after the ethyl acetate extract of mycelium and fermentation liquid is merged
Take the total medicinal extract of object.
3. the separation and purification of compound
After extracting solution total medicinal extract 100-200 mesh silica gel mixed sample, using petroleum ether: methylene chloride: methanol is used as eluent
Depressurize silica gel chromatographic column gradient elution.Eluent obtains active component B(methylene chloride-methanol 50:1 v/v by activity tracking
Eluate), then using petroleum ether: methylene chloride: methanol is further eluted by pressurized silica gel column chromatographic grade as eluant, eluent,
Obtained active subfraction B1(methylene chloride-methanol 20:1 v/v eluate), then with chloroform-methanol (1:2 v/v) for solvent
Sephadex LH-20 gel filtration chromatography is carried out, finally by semi-preparative liquid chromatography (1010 type ODS-A, 10 × 250 mm, 5 μ
M): separation flow velocity be 5 mL/min, mobile phase be 85% acetonitrile contain 0.1% TFA, obtain shown compound (32.1 mg,t R
20.7min).
Compound: light yellow oil, high resolution mass spectrum HRESI-MS existm/z324.2161 place provides molecular ion peak
[M–H]–, (Calcd for C18H30NO4, 324.2175), prompting molecular weight is 325, speculates that molecular formula is in conjunction with spectral information
C18H31NO4。1H and13The NMR datas such as C-NMR are shown in Table 1.
1 compound of table1H and13C-NMR data (500 MHz, CDCl3)a)
The test of 2 anti tumor activity in vitro of embodiment
1. laboratory sample and experimental method
The preparation of sample solution: test sample is the pure compounds of separation and purification in embodiment 1.Precision weighs suitable
Sample is measured, the solution of required concentration is configured to methanol, for surveying activity.
The squamous subculture of cell line and cell uses lung cancer cell line, and cell uses the RPMI-1640 containing 10% FBS to cultivate
Base, 37 DEG C, be passed through 5% CO2Incubator in squamous subculture.
Cell inhibitory effect activity test method
Tetrazolium (MTT) method: cell density is adjusted to every milliliter 2 × 10 by the cell of logarithmic growth phase5A cell,
Be inoculated in 96 porocyte culture plates for 200 microlitres by every hole, in 37 DEG C, be passed through 5% CO2Incubator in cultivate 4 hours.Every hole
2 microlitres of sample liquids or blank solution is added, after culture 24 hours, every hole adds MTT liquid (containing 5 milligrams in every milliliter of physiological saline
MTT) 10 microlitres, continue culture 4 hours, 37 DEG C, 2000 revs/min are centrifuged 8 minutes, suck supernatant.DMSO each 100 is added in every hole
Microlitre, it is vibrated 15 minutes on micro oscillator, until producing SPECTRAMAX Plus type using MD company after crystallization is completely dissolved
Microplate reader measures light absorption value (OD value) of every hole at 570nm.In 96 orifice plate of same, each concentration samples are respectively provided with three holes,
Separately set three hole blank controls and cell-free zeroing hole (if drug has color to do the cell-free zeroing of relative medicine concentration).Each hole
OD value first does corresponding cell-free zeroing, then takes three hole mean OD values, by IR(%)=(ODBlank control-ODSample)/ODBlank control× 100% meter
Calculate cell proliferation inhibition rate (IR%) under each concentration.
2. experimental result
Cell inhibitory effect active testing result
In mtt assay test, according to the proliferation of lung cancer cells inhibiting rate of the compound of various concentration, using SPSS16.0
Software carries out data processing and calculation of half inhibitory concentration IC50Value.It the results are shown in Table 2.
Inhibitory activity of 2 compound of table to proliferation of lung cancer cells
3. conclusion
The compound have apparent proliferation of lung cancer cells inhibiting effect, can be used for preparing proliferation of lung cancer cells inhibitor or
Anti-lung-cancer medicament, for antitumor research.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, is all covered by the present invention.
Claims (2)
1. a kind of alkaloid compound derived from tangerine green trichoderma inhibits the purposes in drug in preparation proliferation of lung cancer cells, special
Sign is: the chemical structural formula of the alkaloid compound are as follows:
；
The compound be by tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4 carry out fermented and cultured, then from
It is isolated in its mycelium and fermentation broth extract；The tangerine green trichoderma (Trichoderma citrinoviride.)
IBPT-4 is deposited in China typical culture collection center on January 25th, 2013, address: Wuhan Wuhan University, and preservation is compiled
Number it is: CCTCC NO:M 2013055.
2. a kind of alkaloid compound derived from tangerine green trichoderma is preparing the purposes in anti-lung-cancer medicament, it is characterised in that: institute
State the chemical structural formula of alkaloid compound are as follows:
；
The compound be by tangerine green trichoderma (Trichoderma citrinoviride.) IBPT-4 carry out fermented and cultured, then from
It is isolated in its mycelium and fermentation broth extract；The tangerine green trichoderma (Trichoderma citrinoviride.)
IBPT-4 is deposited in China typical culture collection center on January 25th, 2013, address: Wuhan Wuhan University, and preservation is compiled
Number it is: CCTCC NO:M 2013055.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610819755.3A CN106491596B (en) | 2016-09-13 | 2016-09-13 | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610819755.3A CN106491596B (en) | 2016-09-13 | 2016-09-13 | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106491596A CN106491596A (en) | 2017-03-15 |
| CN106491596B true CN106491596B (en) | 2019-01-22 |
Family
ID=58290047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610819755.3A Expired - Fee Related CN106491596B (en) | 2016-09-13 | 2016-09-13 | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106491596B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103865807A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol B2 from penicillium citrinum |
| CN103865809A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol B1 from penicillium citrinum |
| CN103865808A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol A1 from penicillium citrinum |
-
2016
- 2016-09-13 CN CN201610819755.3A patent/CN106491596B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103865807A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol B2 from penicillium citrinum |
| CN103865809A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol B1 from penicillium citrinum |
| CN103865808A (en) * | 2014-03-10 | 2014-06-18 | 福州大学 | Novel anti-tumor application of penicillium enol A1 from penicillium citrinum |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106491596A (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103865808B (en) | A kind of anticancer usage of the penicillium sp enol A1 coming from Aspergillus citrimum | |
| CN107298671A (en) | Come from the secalonic acid H of penicillium oxalicum and prepare the application of anti-human colon cancer drug | |
| CN107298672A (en) | The secalonic acid I for coming from penicillium oxalicum is preparing the application of anti-human colon cancer drug | |
| CN104592082B (en) | Come from the penicillium sp enol D of Aspergillus citrimum2preparation method and applications | |
| CN105061446B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting nasopharyngeal carcinoma | |
| CN110407792A (en) | Derived from the secalonic acid class compound Secalonic acid J and preparation method of penicillium oxalicum | |
| CN106491596B (en) | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma | |
| CN106389418B (en) | Derived from tangerine green trichoderma mould enol E1 liver cancer application | |
| CN106420717B (en) | Derived from application of the mould enol E1 in terms of nasopharyngeal carcinoma of tangerine green trichoderma | |
| CN106420715B (en) | Mould enol E1 derived from tangerine green trichoderma is in the application for preparing anti-lymphadenoma drug | |
| CN106432034B (en) | Mould enol E1 derived from tangerine green trichoderma is in the application for preparing anti-breast cancer medicines | |
| CN106432036B (en) | Derived from tangerine green trichoderma mould enol E1 and prepare anti-oral cavity epidermal carcinoma medicinal application | |
| CN106420716B (en) | Derived from application of the mould enol E1 in terms of intestinal cancer of tangerine green trichoderma | |
| CN106491597B (en) | Derived from application of the mould enol E1 in terms of the cancer of the esophagus of tangerine green trichoderma | |
| CN110407797A (en) | Derived from the secalonic acid class compound Secalonic acid K and preparation method of penicillium oxalicum | |
| CN104447475B (en) | Preparation method and application of penicillenol D1 derived from penicillium citrinum | |
| CN106432035A (en) | Application of penem enol E1 derived from trichoderma citrinoviride on the aspect of malignant melanoma | |
| CN106389417B (en) | Derived from application of the mould enol E1 in terms of gastric cancer of tangerine green trichoderma | |
| CN110407794A (en) | Secalonic acid K derived from penicillium oxalicum and the application on inhibition cancer cell multiplication | |
| CN103265522B (en) | Lactone derivative derived from trichoderma citrinoviride and application thereof | |
| CN105061443B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting human liver cancer | |
| CN109134417A (en) | Derived from the application of the secalonic acid I and anti-human cervix cancer drug of penicillium oxalicum | |
| CN107325086B (en) | Citrinin compounds dicitrinone D preparation method and its application in terms of colon cancer | |
| CN105061445B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting human gastric cancer | |
| CN105131006B (en) | Penicitrinine A sourced from penicillium citrinum and application thereof in preparation of anti-malignant melanoma drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190122 Termination date: 20210913 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |